Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 5.97% is 29% below its 1-year average of 8.43%, near the low end of its 1-year range (5.97%–10.78%).
As of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
RETURN ON EQUITY (ROE)
5.97%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
-54.10%
vs the sector median at left
Market Cap
$30.02B
Return on Equity (ROE)
14.51%
TTM Avg
21.84%
3Y Avg
21.53%
5Y Avg
32.27%
Market Cap
$30.64B
Return on Equity (ROE)
1.09%
TTM Avg
29.98%
3Y Avg
64.02%
5Y Avg
111.55%
Market Cap
$30.82B
Return on Equity (ROE)
83.10%
TTM Avg
66.19%
3Y Avg
56.82%
5Y Avg
52.60%
Market Cap
$31.54B
Return on Equity (ROE)
4.43%
TTM Avg
8.42%
3Y Avg
11.86%
5Y Avg
16.52%
Market Cap
$26.44B
Return on Equity (ROE)
11.65%
TTM Avg
9.71%
3Y Avg
9.35%
5Y Avg
12.84%
Market Cap
$31.77B
Return on Equity (ROE)
-22.60%
TTM Avg
-10.46%
3Y Avg
-1.37%
5Y Avg
1.10%
Market Cap
$26.31B
Return on Equity (ROE)
7062.40%
TTM Avg
-2178.82%
3Y Avg
-341.14%
5Y Avg
-117.12%
Market Cap
$31.88B
Return on Equity (ROE)
38.14%
TTM Avg
28.93%
3Y Avg
25.01%
5Y Avg
22.95%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medline Inc. (MDLN) | $29.07B | 5.97% | N/A | N/A | N/A |
| GE HealthCare Technologies Inc. (GEHC)vs › | $30.02B | 14.51% | 21.84% | 21.53% | 32.27% |
| Waters Corporation (WAT)vs › | $30.64B | 1.09% | 29.98% | 64.02% | 111.55% |
| Zoetis Inc. (ZTS)vs › | $30.82B | 83.10% | 66.19% | 56.82% | 52.60% |
| Biogen Inc. (BIIB)vs › | $31.54B | 4.43% | 8.42% | 11.86% | 16.52% |
| Labcorp Holdings Inc. (LH)vs › | $26.44B | 11.65% | 9.71% | 9.35% | 12.84% |
| Centene Corp. (CNC)vs › | $31.77B | -22.60% | -10.46% | -1.37% | 1.10% |
| Mettler-Toledo International Inc. (MTD)vs › | $26.31B | 7062.40% | -2178.82% | -341.14% | -117.12% |
| DexCom, Inc. (DXCM)vs › | $31.88B | 38.14% | 28.93% | 25.01% | 22.95% |
| ResMed Inc. (RMD)vs › | $31.91B | 23.13% | 23.30% | 22.33% | 21.49% |
ROE
6.0%
ROA
1.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 5.97% |
| 2026-03-31 | 8.55% |
| 2025-12-31 | 10.78% |
